Table 3.
Clinical characteristics of the whole PD patient’s sample.
| p | ||
|---|---|---|
|
| ||
| Age at onset (years) a | 61 ± 10.86 | <0.0001 |
| 50 years or less (EOPD) | 19.8% | |
| 51 years or more (LOPD) | 80.2% | |
|
| ||
| Disease duration (years)b | 6 ± 5.38 | |
| EOPDc | 8 (0–28) | |
| LOPDc | 5 (0–22) | <0.001 |
|
| ||
| Hoehn and Yahr staged | 2 (1–5) | |
| EOPD | 2 (1–3) | |
| LOPD | 2 (1–5) | 0.038 |
|
| ||
| Initial motor symptoms (n)e | ||
| Tremor (138) | 52.7% | |
| Postural instability (16) | 6.1% | |
| Tremor and instability (31) | 11.8% | |
| Other(77) | 29.4% | <0.0001 |
| EOPDe | ||
| Tremor | 43.5% | |
| Postural instability | 8.7% | |
| Tremor and instability | 6.5% | 0.0002 |
| Other | 41.3% | |
| LOPDe | ||
| Tremor | 61.9% | |
| Postural instability | 5.4% | |
| Tremor and instability | 12.0% | <0.0001 |
| Other | 20.7% | |
|
| ||
| Pharmacological treatmentf | 5% | |
| Dopamine agonist therapy (DA) | ||
|
| ||
| Levodopa therapy | 40.6% | |
|
| ||
| DA+Levodopa therapy | 51.9% | <0.0001 |
|
| ||
| Other therapy | 2.5% | |
a
EOPD vs LOPD Chi square; significant differences were observed. p<0.001; mean ± standard deviation is reported.
b
Mean ± standard deviation is reported.
c
Median (Min-Max) is reported; U Mann-Whitney between disease duration and age at onset were made. p<0.001.
d
Median (Min-Max) is reported; Spearman correlation between disease duration and Hoehn and Yahr were made. p<0.001; U Mann-Whitney between Hoehn and Yahr and age at onset were made. p=0.038
e
Type of initial motor symptom (4x1) Chi square; differences were observed. p<0.001; n and % is reported.
f
Type of pharmacological treatment (4x1) Chi square; differences were observed. p<0.001; % is reported.